Drug Approval | February 05, 2026
Strides Pharma Inc receives USFDA closure report for Chestnut Ridge formulations facility
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Inspection included drug device combinations covering our recent filing in nasal sprays domain
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
The platform is being introduced to expand access to treatments for people living with chronic conditions
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
A triple-action Formula for comprehensive respiratory relief
Subscribe To Our Newsletter & Stay Updated
